Therapeutic Oligonucleotides for Neurodegenerative Diseases: Aptamer Strategies and Clay Nanoparticle‐Based Delivery
The Chemical Record · 2025
DOI: 10.1002/tcr.202500126 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Chemical Record, 2025. Verfasst von Valentina Arciuolo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Naples Federico II, 80131, Naples, Italy. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Aptamers, Nucleotide, Nanoparticles, Oligonucleotides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 260 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, European Union - Next Generation EU.
Abstract (Originalsprache)
Aptamers have emerged as promising therapeutic oligonucleotides (TOs) due to their structural adaptability, high binding affinity, and remarkable specificity toward diverse biological targets. Among them, G‐quadruplex‐forming aptamers stand out for their unique secondary structures and distinct chemical properties. Their potential in neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's lies in their ability to inhibit protein aggregation and modulate pathogenic pathways. However, their application is hindered by enzymatic degradation and limited membrane permeability. To overcome these issues, chemical modifications, such as backbone and sugar alterations, and nanomaterial‐based delivery strategies have been developed. Notably, clay nanoparticles, such as halloysite nanotubes and montmorillonite, have gained attention as effective carriers for TOs, enhancing their structural stability and bioavailability. This review discusses recent advancements in aptamer‐based TOs, with a focus on G‐quadruplex‐forming oligonucleotides, their therapeutic potential in neurodegenerative diseases, and innovative nanocarrier systems that can improve their stability and targeted delivery. Finally, it highlights current challenges and future directions in the chemical design and formulation of aptamer‐based therapeutics for targeted applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Naples Federico II, 80131, Naples, Italy.
- Department of Physics and Chemistry - Emilio Segrè, University of Palermo, 90128, Palermo, Italy.
ORCID-Profile: Valentina Arciuolo, Maria Rita Caruso, Martina Maria Calvino, Jussara Amato, Giuseppe Lazzara, Stefana Milioto, Concetta Giancola, Giuseppe Cavallaro, Bruno Pagano
Förderung
- Ministero dell'Università e della Ricerca
- European Union - Next Generation EU
Zitieren
APA
Arciuolo, V., D'Aria, F., Caruso, M. R., Calvino, M. M., Amato, J., Lazzara, G., Milioto, S., Giancola, C., Cavallaro, G., & Pagano, B. (2025). Therapeutic Oligonucleotides for Neurodegenerative Diseases: Aptamer Strategies and Clay Nanoparticle‐Based Delivery. The Chemical Record. https://doi.org/10.1002/tcr.202500126
Vancouver
Arciuolo V, D'Aria F, Caruso MR, Calvino MM, Amato J, Lazzara G, et al. Therapeutic Oligonucleotides for Neurodegenerative Diseases: Aptamer Strategies and Clay Nanoparticle‐Based Delivery. The Chemical Record. 2025. doi:10.1002/tcr.202500126
BibTeX
@article{Arciuolo2025,
author = {Arciuolo, Valentina and D'Aria, Federica and Caruso, Maria Rita and Calvino, Martina Maria and Amato, Jussara and Lazzara, Giuseppe and Milioto, Stefana and Giancola, Concetta and Cavallaro, Giuseppe and Pagano, Bruno},
title = {Therapeutic Oligonucleotides for Neurodegenerative Diseases: Aptamer Strategies and Clay Nanoparticle‐Based Delivery},
journal = {The Chemical Record},
year = {2025},
doi = {10.1002/tcr.202500126}
}
EUVIMED